StemCell Therapy

Posted By MyUVicLife on Oct 30, 2019 in Hands-on learning, Student life

On the weekend of October 4th, our team participated in this years Health and Regenerative Medicine Hackathon. We thought we would give a quick recap of the event as well as share our experience with you.

By: Natalie Koehn, Jacqui Moreland, Kim Arklie and Jacky Le

The second annual Health and Regenerative Medicine Hackathon was held at FortTectoriain downtown Victoria during the first weekend of October.

Traditionally, a hackathon is a competition where people gather to tackle coding and programming related challenges in a consecutive period of 24-48 hours. However, the Health and Regenerative Medicine Hackathon is different! The challenges as its name suggests are related to health and medicine. Due to the nature of the challenges, competitors were allowed to work on their designs during the month leading up to the Hackathon weekend.

The following challenges were presented to us by various organizations involved in Victorias health industry:

As a combined team of biomedical and mechanical engineers from the University of Victoria, we are passionate about creating assistive technology to solve health-related problems. We had worked together in a school group project in the past and were looking to find another opportunity to work together and design something meaningful.

Inspired by their patient stories and their mission to provide low-cost healthcare opportunities to developing countries, we were eager to take on the Victoria Hand Projects (VHP) challenge to create an assistive device to allow children to write.

A 3D printed solution was optimal for both the rapid prototyping of the Hackathon but also was one of the design requirements for the given project.

In the two weeks leading up to the Hackathon, we came up with a general design concept consisting of two major components an attachment mechanism to the prosthetic hand and a clamping mechanism for the writing utensil. A few iterations were made as a result of tests performed on our original design.

This led us to our final product that utilizes a three-prong and elastic mechanism to grasp the pencil. The pencil is housed in a cylindrical tube, held in place at an optimal angle, that attaches to a simple support that wraps around the bottom of the hand. The hand rests on a bed of silicone at the base of the device in order to prevent unwanted movement, and tightly secured with avelcrostrap.

It was inspiring coming together on the final day of the Hackathon to see the hard work of each group come to life to create such a wide range of solutions. The panel of judges, sponsors and professionals that attended the event were just as passionate about the projects as we were. They provided feedback and support to the teams throughout the Hackathon and helped make the event possible.

All in all, it was a great opportunity and we are looking forward to participating in next years Hackathon. We encourage anyone who is interested in STEM related fields to engage in opportunities like this and explore the design world in a fun, out of school environment!

The views expressed in this blog are my own, and do not necessarily reflect the policies or views of the University of Victoria. I monitor posts and comments to ensure all content complies with the University of Victoria Guidelines on Blogging.

More:
2019 Health and Regenerative Medicine Hackathon - University of Victoria News

SELBYVILLE, Del., Nov. 5, 2019 /PRNewswire/ -- The global Cancer Gene therapy market'srevenue is expected to surpass USD $2.5 billion by 2025, according to a new research report by Global Market Insights, Inc. Rising government initiatives in emerging economies for promoting developments in gene therapies will positively impact the cancer regenerative medicine market's growth. The government often implements several laws and initiatives to motivate scientists and researchers to perform extensive analysesof gene therapies. Furthermore, the government also funds various studies that are carried out for developing molecular therapies utilized in the treatment of cancer. The aforementioned factors should escalate the industry's growth.

There have been several advancements in the biotechnology sector that have proven beneficial for the industry's growth. Several viral vectors have been introduced in the market that work efficiently for carrying out gene transfers. Researchers vigorously work on studying the efficacy and efficiency of the viral, as well as non-viral, vectors that are utilized in gene therapy. Newly developed viral vectors are capable of inhibiting the growth of tumor-inducing genes and are preferred by biopharmaceutical companies. Moreover, healthcare professionals working on gene therapy have started trusting and preferring these viral vectors for treating cancer patients. Therefore, growing advancements will ensure the availability of superior quality vectors for gene transfer, which will foster the market's growth.

Request for a sample of this research report athttps://www.gminsights.com/request-sample/detail/763

The types in the cancer gene market are categorized into in-vivo and ex-vivo. The in-vivo segment of the cancer gene therapy market was valued over USD $350 million in 2018 and will experience substantial growth throughout the analysis period. In-vivo gene therapy is a cost-effective option since it avoids the tedious process of removing cells from a patient's body. Furthermore, in-vivo cancer gene therapy is widely expected to treatcystic fibrosis, which positively influences business growth. However, in recent times, several high-profile, adverse events pertaining to gene therapies were recorded that has reduced its demand, therebylowering the pace of segmental growth.

Based on product, the global market is bifurcated into viral vectors and non-viral vectors. The viral vectors segment of cancer gene therapy is anticipated to foresee around 23% growth throughout the analysis timeframe. Adenovirus is one of the highly preferred viral vectors that has commendable transductional efficiency that raises its adoption. Moreover, theadenovirus vector reduces the risk of mutagenesis. Besides, other viral vectors are also efficient and enable long-term DNA expression, reducing the mortality rate in patients suffering from cancer. The aforementioned factors will spur the viral vectors' segment growth.

Cancer Gene Therapy Market Growth, By Product

5.1. Key segment trends

5.2. Viral vectors5.2.1. Market size, by region, 2014 2025 (USD Million)5.2.2. Adenoviruses5.2.2.1. Market size, by region, 2014 2025 (USD Million)5.2.3. Lentiviruses5.2.3.1. Market size, by region, 2014 2025 (USD Million)5.2.4. Retrovirus5.2.4.1. Market size, by region, 2014 2025 (USD Million)5.2.5. Adeno associated virus5.2.5.1. Market size, by region, 2014 2025 (USD Million)5.2.6. Herpes simplex virus5.2.6.1. Market size, by region, 2014 2025 (USD Million)5.2.7. Vaccinia virus5.2.7.1. Market size, by region, 2014 2025 (USD Million)5.2.8. Others5.2.8.1. Market size, by region, 2014 2025 (USD Million)

5.3. Non-viral vectors5.3.1. Market size, by region, 2014 2025 (USD Million)

5.4. Others5.4.1. Market size, by region, 2014 2025 (USD Million)

Browse key industry insights spread across 95 pages, with 120 market data tables and eight figures and charts from the report,Cancer Gene Therapy Market Size By Type (Ex-vivo, In-vivo), By Product (Viral Vectors {Adenoviruses, Lentiviruses, Retrovirus, Adeno Associated Virus, Herpes Simplex Virus, Vaccinia Virus}, Non-viral Vectors), By End-use (Biopharma Companies, Research Institutes), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China), Price Trends, Application Potential, Competitive Market Share & Forecast, 2019 2025," in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/cancer-gene-therapy-market

The end-use segment of cancer gene therapy includes biopharmaceutical companies, research institutes and others. The research institutes segment held around a 40% revenue share in 2018. Significant segmental growth can be attributed to the increasing demand for viral vectors by research institutes that work on cancer gene therapies. Research institutes constantly focus on assessing the efficacy of gene therapies by using different vectors. Moreover, vector manufacturing companies develop superior quality viral, as well as non-viral, vectors that will positively influence the segmental growth.

The U.K. market accounted for around USD $35 million in 2018 and is projected to witness momentous growth during the analysis timeframe. The increasing adoption of cancer gene therapy due to considerably high purchasing power has augmented the cancer gene therapy market growth in the country. Furthermore, the increasing prevalence of cancer has positively influenced the industry's growth. According to a study, in 2017, around 164,901 people died from cancer in the U.K., which creates demand for advanced gene therapies for treating cancer.

Make an inquiry for purchasing this report athttps://www.gminsights.com/inquiry-before-buying/763

Browse Related Reports:

Cancer Diagnostics Market Statistics 2025: Breast cancer is one of the most frequent cancers among womenacross the globe. According to the World Health Organization (WHO), about 2.1 million women are suffering from breast cancer each year. Also, breast cancer rates are higher among women in more developed countries than in developing and under-developed economies. A few prominent players operating in the global market are Abbott, Roche, Siemens Healthcare, Danaher Corporation, Becton, GE Healthcare, Dickinson and Company (BD), Janssen Diagnostics among others.

https://www.gminsights.com/industry-analysis/cancer-diagnostics-market

About Global Market Insights

Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services. Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making. These exhaustive reports are designed via a proprietary research methodology and are available for key industries such as chemicals, advanced materials, technology, renewable energy and biotechnology.

Contact Us:

Arun HegdeCorporate Sales, USAGlobal Market Insights, Inc.Phone:1-302-846-7766Toll Free:1-888-689-0688Email:sales@gminsights.com

Related Images

cancer-gene-therapy-market.jpg Cancer Gene Therapy Market Forecasts 2025 Cancer Gene Therapy Market is set to register over a 22% CAGR up to 2025, driven by the rising prevalence of cancer in developed, as well as developing, economies.

Related Links

Cancer Gene Therapy Market size

Cervical Cancer Diagnostic Market

SOURCE Global Market Insights, Inc.

https://www.gminsights.com

View post:
Cancer Gene Therapy Market Value to Hit $2.5 Billion by 2025: Global Market Insights, Inc. - PRNewswire

Toronto, ON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Notch Therapeutics, a company in the emerging field of gene-modified T cell therapy, has been created to commercialize a revolutionary technology that creates allogeneic (donor) gene-edited T cells from stem cells on an industrial scale, efficiently making T cell therapies that are clinically robust and of a consistently high quality. Notch is actively pursuing industry partnerships.

The founders of Notch - Sunnybrook Health Sciences Centre, University of Toronto (UoT), Toronto Innovation Acceleration Partners (TIAP) and CCRM, with Lumira Ventures as an additional investor - created Notch to provide a vehicle through which to further develop and bring to market the combined pioneering research, nearly ten years underway, from the labs of Drs. Juan CarlosZiga-Pflcker,Senior Scientistin Biological Sciences atSunnybrook,and Chair of the Department of Immunology atUoT;andof Peter Zandstra,Professor, Institute of Biomaterials and Biomedical Engineering at UoTandDirector, School of Biomedical engineering and Michael Smith Laboratories at the University of British Columbia.

"This technology is very promising and might be used to create therapiesto treatsome of our greatest medical challenges,like cancer, autoimmune diseases and organ transplant rejection. Its also the first and only method that can reconstitute immune systems," says Dr. Andy Smith, President and CEO of Sunnybrook Health Sciences Centre. "Finally having optionstotarget these high-impact areasfor our patientsis what we mean when we say we are inventing the future of health care."

Jennifer Fraser, Director Innovations at the University of Toronto, comments that "Dr. Ziga-Pflckers allogeneic T cell therapy was one of the first projects I worked on when I joined UoT. Its very gratifying to see the technology move toward the clinic."

Even as the field for these therapies grows rapidly, major challenges have until now prevented wider adoption mainly due to a slow and expensive manufacturing process which yielded variable results. The Notch technology, however, shows promise for surmounting these issues cost-effectively and reliably. Notch, having been incubated at CCRM, will be able to leverage its in-house process development expertise and Good Manufacturing Practices (GMP) facility, located in downtown Toronto. It offersuniversally enhanced T cell therapies against high-impact diseases, using stem cells as a renewable source to expand treatment options and deliver cost-effective immunotherapies to patients. The aim of Notch is to generate T cells from multiple sources of stem cells and provide a platform for research and development, and a better way of manufacturing T cells and their applications for treating cancers or immune deficiencies.

"TIAP is pleased that, after many years of nurturing this research and investing in the risky early-stages with our co-founders, we are now seeing a truly ground-breaking new health science technology make its way through development in a very encouraging way. This is yet another example of what can be done through TIAPs unique ability within the community to bundle technologies across multiple institutions. This is a true collaboration which has resulted in development of a technology that will have significant impact", says Dr. Rafi Hofstein, President & CEO of TIAP.

"Notch Therapeutics is a star pupil in CCRMs incubation program," says Dr. Michael May, President and CEO of CCRM. "By de-risking the technology and designing Proof of Concept studies to appeal to investors, attracting experienced start-up management, and working with our ecosystem partners, we have collectively given Notch every opportunity to succeed."

Dr. Benjamin Rovinski, Managing Director of Lumira Ventures, states: "Early on, our team recognizedNotchs novel and differentiated platform and its potential to produce safer, more effective, and scalable allogeneic T cell therapies. We are pleased to be part of the financing syndicate. The quality and breadth of science coming out of Canadian universities is phenomenal, and important innovators like Notch are able to access capital, knowledge and the engaged support of Lumira and other investors, to enable the development and commercialization of their technology. We are excited to work with the entire Notch team."

About TIAP

TIAP is a leading provider of venture building services, early-stage funding, and deal-brokering with industry and private investors. As a member-based organization made up of 14 member institutions including University of Toronto and affiliated teaching hospitals TIAPs mandate is to drive the commercialization of their most promising research breakthroughs. TIAP has an active portfolio of more than 60 companies in sectors such as therapeutics, medical devices and IT/AI, which have raised in excess of CDN$300M from global investors, and has created more than 1000 direct/indirect jobs.

For more information, please visit http://www.tiap.ca

About University of TorontoFounded in 1827, the University of Toronto is Canadas leading institution of learning, discovery and knowledge creation. U of T is one of the worlds top research-intensive universities, driven to invent and innovate. It is also one of the top five universities in the world for its start-up incubator programs. In the last 10 years, the U of T entrepreneurship community has created over 500 companies and raised over $1.5 billion in investment capital. http://www.utoronto.ca

About Sunnybrook Health Sciences CentreSunnybrook Health Sciences Centre is inventing the future of health care for the 1.3 million patients the hospital cares for each year through the dedication of its more than 10,000 staff and volunteers. An internationally recognized leader in research and education and a full affiliation with the University of Toronto distinguishes Sunnybrook as one of Canadas premier academic health sciences centres. Sunnybrook specializes in caring for high-risk pregnancies, critically-ill newborns and adults, offering specialized rehabilitation and treating and preventing cancer, cardiovascular disease, neurological and psychiatric disorders, orthopaedic and arthritic conditions and traumatic injuries. The Hospital also has a unique and national leading program for the care of Canadas war veterans. For more information about how Sunnybrook is inventing the future of health care. Please visit us online at http://www.sunnybrook.ca

About CCRMCCRM, a Canadian not-for-profit organization funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. CCRM is the commercialization partner of the Ontario Institute for Regenerative Medicine and the University of Torontos Medicine by Design. CCRM is hosted by the University of Toronto. Visit us atccrm.ca.

About Lumira VenturesLumira Ventures isCanadasleading and most active healthcare venture capital firm. Lumira invests in best-in-class North American companies developing innovative therapeutics and medical technologies whose products offer transformative improvements to patient health outcomes and provide meaningful reductions to the overall cost of healthcare delivery. Since inception, Lumiras portfolio companies have brought 50+ new therapies to market, impacting the lives of 1+ billion patients globally, generating $65+ billion in cumulative revenue.

For more information, please visit http://www.lumiraventures.com

See the rest here:
Notch Therapeutics a new company with a revolutionary allogeneic ("off the shelf") T cell technology - GlobeNewswire

GERMANTOWN, Md., Nov. 4, 2019 /PRNewswire/ -- Intrexon Corporation(NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release third quarter financial results before the market opens on Tuesday, November 12th, 2019. Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients and a wholly owned subsidiary of Intrexon, will host a conference call that day at 11:00 AM ET to provide Precigen business and pipeline updates.

The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada), and 1412-317-6061(International) and providing the number 4454504 to join the Precigen Business and Pipeline Update Call. Participants may also access the live webcast through Intrexon's website in the Investors section at http://investors.dna.com/eventsor Precigen's website in the Presentations section at https://precigen.com/media/#id-presentations.

About Intrexon Corporation Intrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNA to create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more at http://www.dna.comor follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.

About Precigen : Advancing Medicine with Precision Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Precigen also follows the science opportunistically in pursuit of promising programs in emerging therapeutics. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. Precigen was founded as a wholly owned subsidiary of Intrexon Corporation(NASDAQ: XON) and leverages a diverse portfolio of technology platforms to advance human health. For more information about Precigen, visit http://www.precigen.comor follow us on Twitter @Precigenand LinkedIn.

Trademarks Intrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.

Safe Harbor Statement Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Intrexon Investor Contact:

Steven Harasym

Vice President, Investor Relations

Tel: +1 (301) 556-9850

investors@dna.com

Intrexon Corporate Contact:

Marie Rossi, PhD

Vice President, Communications

Tel: +1 (301) 556-9850

publicrelations@dna.com

Precigen Media Contact:

Donelle M. Gregory

press@precigen.com

Continued here:
Intrexon to Announce Third Quarter Financial Results on November 12th - Herald-Mail Media

- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis

- Partnership incorporates Cryoport's Cryoportal Logistics Management Platform, SmartPak II Condition Monitoring System and Cryoport's unique Chain of Compliance for regulatory solutions.

- Partnership builds on the recently announced partnership between Lonza and Vineti with an aim to provide cell and gene therapy developers with a fully integrated delivery solutions including manufacturing, supply chain orchestration and logistics, globally

BASEL, Switzerland and IRVINE, Calif., Nov. 5, 2019 /PRNewswire/ --

Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:"The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients. There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency."

Quote from Jerrell Shelton, CEO, Cryoport:"Clinical trial activity in the cell and gene therapy sector is rapidly growing as biopharmaceutical companies discover new ways to harness regenerative therapies and combat illnesses. As more and more of these therapies approach commercialization, there is strengthening demand for reliable, integrated outsourced manufacturing and distribution solutions. Our partnership agreement with Lonza, an internationally-renowned supplier to the pharma and biotech markets, will improve effectiveness, efficiency and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza's manufacturing services."

Lonza (LONN.SW) and Cryoport, Inc. (CYRX) ("Cryoport"),announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza's customers and their patients. Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics -- including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines -- as they prepare for the commercial launch of their respective therapies.

Lonza's network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport's logistics andbioservices solutions with Lonza's manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.

The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry, and process optimization that reduces risk, increases transparency and improves certainty.

Story continues

Cryoport's logistics system aims to provide Lonza's clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals. Beyond Cryoport's proprietary Cryoport Express Shippers, this partnership incorporates Cryoport's Cryoportal Logistics Management Platform and SmartPak II Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport's unique Chain of Compliance for regulatory solutions.

About Lonza Lonza is an integrated solutions provider that creates value along the Healthcare Continuum. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.

Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found atwww.lonza.com.

About CryoportCryoport, Inc. (CYRX) is the world'spremier provider of temperature-controlled supply chain solutions for the life sciences industry,serving the Biopharma, Human Reproductive, and Animal Health markets. Our mission is to support life and health on earth by providing reliable and comprehensive solutions for the life sciences through our advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting team of professionals. Through purpose-built proprietary packaging; information technology; smart, sustainable cold chain logistics; and biostorage/biobanking services, Cryoport helps its customers advance life sciences research, support life-saving advanced therapies and deliver vaccines, protein producing materials, and IVF treatments in over 100 countries around the world. For more information, visit http://www.cryoport.com or follow @cryoport on Twitter atwww.twitter.com/cryoport for live updates.

Additional Information and Disclaimer (Lonza)Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Forward Looking Statements (Cryoport)Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Company's 10-K for the year ended December 31, 2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/lonza-partners-with-cryoport-and-strengthens-its-vein-to-vein-delivery-network-in-cell--gene-therapy-300950920.html

Read the original:
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy - Yahoo Finance

As a member of the daytime community for many years, Don Diamont has seen soaps tackle important social issues. Now, the star of The Bold and the Beautiful is lending his name to a topical and vital concern.

The actor was invited recently to speak at the annual ISSCR (International Society for Stem Cell Research Conference) in Los Angeles. He accepted to show his support for a dear pal, who is battling ALS.

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference, Diamont posted on his Instagram account. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS.

Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI, Diamont continued. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in any way to fight the good fight in eliminating this horrible illness, thank you!

Diamont concluded his post with words of encouragement for his friend: Nanci, you are the bravest of the brave! I, and we LOVE YOU

Soap fans may recall that the late Michael Zaslow (ex-Roger, Guiding Light; ex-David, One Life to Live) had been diagnosed with the disease. He passed away in 1998. For more information on ALS, click here. The Bold and the Beautiful airs weekdays on CBS. Check local listings for air times.

View this post on Instagram

I was touched, and humbled to be asked to speak for, and about my beloved friend Nanci Ryder at this years ISSCR Conference. The event is the largest gathering of stem cell scientists and clinicians in the world. Nancis story is a powerful one, and I was honored to have an opportunity to share it with those on the front lines in the battle to find a cure for ALS. Yesterday, at The Walk to Defeat ALS, I was with Nanci and the group of wonderful souls that make up TEAM NANCI. Thank you to the @alsagoldenwest chapter for all that you do! Thank you to Dr. Justin Ichida! Justin is the Assistant Professor of Stem Cell and Regenerative Medicine at the Keck School of Medicine USC. Hes making significant strides in moving toward a cure for ALS. Finally, to anybody out there whos helping in anyway to fight the good fight in eliminating this horrible illness, thank you! Nanci, you are the bravest of the brave! I, and we LOVE YOU

A post shared by Don Diamont (@dondiamont) on Nov 4, 2019 at 4:15pm PST

03:31

Dollar Bill Tribute

Video Credit: SunRiseIta

See original here:
The Bold and the Beautiful Star Don Diamont Supports ALS Research - Soap Hub

Masume Bayat,1 Seyed Ahmad Raeissadat,2 Maryam Mortazavian Babaki,3 Shahram Rahimi-Dehgolan4

1Physical Medicine and Rehabilitation Department of Mahdiyeh Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Clinical Development Research Center of Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 3Physical Medicine and Rehabilitation Department & Research Center, Shohada-E-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Physical Medicine and Rehabilitation Department of Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

Correspondence: Maryam Mortazavian BabakiNo. 1989934148, Shohada-e-Tajrish Hospital, Tehran, IranTel +982122731112Fax +982122724210Email maryam_m.babaky@sbmu.ac.ir

Purpose: To compare the efficacy of dextrose prolotherapy versus steroid injection in the treatment of patients with chronic lateral epicondylitis.Methods: Thirty subjects with chronic lateral epicondylitis were randomly assigned into two groups of hypertonic dextrose or methylprednisolone injection. Participants were assessed through Quick DASH and VAS scores, once before injection, and then after 1- and 3-months follow-up. Two patients were excluded due to not completing the follow-up timepoints.Results: In both groups VAS scores revealed significant improvement during the first month follow-up [mean difference (MD) = 1.93.3, versus 1.51.9 for the prolotherapy and steroid groups, respectively]. This declining trajectory continued at the third month visit in the prolotherapy group and MD reached 4.42.9, while it did not change remarkably in the steroid group (MD=1.93.4). In fact, comparing VAS scores between the 1st- and 3rd-month time points did not reveal a significant improvement in the steroid group (p=0.6). Also, the Quick DASH index showed a similar pattern and improved remarkably in both groups during the first visit. However, only the efficacy in the prolotherapy group persisted after 3-month follow-up (MD = 9.521.6, p=0.044). One month after injections no preference between the two interventions was observed (p=0.74 for VAS and 0.14 for Quick DASH score). However, the 3rd-month follow-up revealed a meaningful superiority (p=0.03 for VAS and p=0.01 for Quick DASH score) favoring the prolotherapy method.Conclusion: Both methods were proven to be effective in the short-term treatment of chronic lateral epicondylitis, but dextrose prolotherapy seems to be slightly more efficacious than steroid injection over a longer period.Clinical trial registration: Iranian Registry of Clinical Trials Database: IRCT20170311033000N3.

Keywords: regenerative medicine, tennis elbow, methylprednisolone, prolotherapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Go here to see the original:
Is Dextrose Prolotherapy Superior To Corticosteroid Injection In Patie | ORR - Dove Medical Press

Last week, the Cystic Fibrosis Foundation launched a new initiative called Path to a Cure. A press release called it an ambitious research agenda to deliver treatments for the underlying cause of the disease and a cure for every person with cystic fibrosis (CF).

It added: The Foundation is challenging potential collaborators to submit proposals that will accelerate the pace of progress in CF drug discovery and development and intends to allocate half a billion dollars to the effort through 2025.

News of the initiative comes nine days after an announcement by the U.S. Food and Drug Administration that it has approved the highly anticipated treatment Trikafta, a triple combination therapy of ivacaftor, tezacaftor, and the new elexacaftor (VX-445). Trikaftas clinical trial outcomes were remarkable and on par with the early clinical results from the highly effective Kalydeco several years ago, especially when compared with the outcomes of the not very robust but efficacious Orkambi and Symdeko.

The foundations strategic plan for the next five years is audacious, but I think its an honest pursuit. A year ago, I wrote about what a cure for CF might look like, and I discussed how the progressive and chronic nature of CF makes curing it a sort of nebulous concept.

In CF, the broken protein that is the underlying cause of the disease isnt the killer. The killers are the recurring infections, the inflammation, and the downstream effects of the broken cystic fibrosis transmembrane conductance regulator (CFTR) protein. Due to recurring infections, the lungs become damaged, and endemic bacteria become more resistant to traditional antibiotics.

For someone with moderate lung disease, fixing the underlying issue wont heal the scar tissue or reconstruct damaged airways. Most people with CF are pancreatic insufficient. Theoretically, an embryonic cure would prevent sustained damage to any part of the body. Once birth occurs, however, a cure would be too late to prevent even the slightest damage.

In the column from last year, I also wrote: Im not saying a cure is impossible or undesirable. Rather, there are multiple pillars to ultimately curing all the ills that deeply affect our lives. I think looking at a cure in this way is a reason to be hopeful. I added that I didnt believe this change of perspective about what a cure looks like should be a reason for discouragement.

What I like about the CF Foundations Path to a Cure is how theyre discussing what the different paths look like. Current therapies are modulators. At best, they repair CFTR protein, which is different than fixing or replacing it. This initiative also emphasizes the most important tenet of all CF therapies: It is intended to help everyone with CF. Complicated mutations will require different strategies.

A cure for cystic fibrosis is a complicated endeavor. CF is a particularly interesting genetic disease for many reasons, not least of which is that the pathway to curing it could be extrapolated to other diseases with genetic causes or predispositions. I do believe a cure is possible, though Im usually cautious to offer my commentary on the word cure.

Many subpopulations exist in the CF community. Thousands of people in the world have CF. A percentage of that population doesnt have access to the most basic CF treatments. Many people in the United States dont even have good access or care. Modulators arent approved for transplant patients.

Its not for nothing that the CF Foundation and the community itself must ask one important question: What does life look like for someone with feeble lung function that is cured of CF? If other treatment plans arent in place such as better transplant strategies utilizing stem cells, or using stem cells for lung regeneration a cure may not prolong life, but rather prolong the misery of end-stage disease.

Part of planning for the future is predicting the effects of that plan. But we must ask: How are we giving everyone with CF the chance to live well into their 70s and 80s? I think the important discoveries made along the way will be instrumental in learning if its possible to repair diseased lungs through regenerative medicine.

Path to a Cure is one of the most exciting research agendas weve seen. Im looking forward to the day when the CF Foundation announces that a cure has been found.

Follow along with my other writings on my humbly named site, http://www.trelarosa.com.

***

Note: Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Cystic Fibrosis News Today, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to cystic fibrosis.

Read this article:
What We Should Expect from the CF Foundation's 'Path to a Cure' - Cystic Fibrosis News Today

A huge leap could be made with bioprinting the 3D printing of tissue and organs thanks to an innovative idea which proposes to use aqueous architectures, or in other words, printing in a specially made fluid.

As Science magazine reports, human tissue and organs are very tricky to make using traditional 3D printing methods without putting support scaffolding in place and that scaffolding can later be very difficult (or indeed impossible) to remove.

So the idea as advanced by Chinese researchers is to move away from a solid support structure, and instead use liquid. Specifically, this would be a fluid matrix into which the liquid design for an organ could be injected, and the surrounding fluid then drained away after the organ has set.

This kind of approach has previously been attempted, except the fluid matrix hasnt proven stable enough, and the whole thing has simply collapsed. So instead these researchers from China have used hydrophilic (attracted to water molecules) liquid polymers which are capable of creating a stable membrane.

Using this method, the liquid structure is far more robust and is even capable of holding its shape for as long as 10 days. A further benefit is that during the process of pumping the ink into the fluid membrane, if mistakes are made, the nozzle can actually extract and rewrite the ink as needed.

The researchers believe that this advance in the field of bioprinting will help greatly with the production of complex tissue-like constructs including arteries and tracheae.

And this could have a major impact in terms of regenerative medicine, the scientists say, as well as producing in-vitro tissue models for studies and the likes of disease modeling, or potential applications like drug screening or development.

The researchers note that a commercially available 3D printer has been used in their early experiments thus far, albeit when printing multiple cells, a homemade microuidic nozzle head was employed instead.

See the original post here:
3D printing could have cracked the problem of making human organs - TechRadar

NEW YORK, Nov. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the third quarter ended September 30, 2019, and provide a corporate update, at 8:00 a.m., Eastern Standard Time, on Thursday, November 14, 2019.

BrainStorms President & CEO, Chaim Lebovits, will present a corporate update, after which, participant questions will be answered. Joining Mr. Lebovits to answer investment community questions will be Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer, and Preetam Shah, PhD, Chief Financial Officer.

Participants are encouraged to submit their questions prior to the call by sending them to: q@brainstorm-cell.com; Questions should be submitted by 5:00 p.m., Eastern Standard Time, Tuesday, November 12.

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF) cells represent a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. BrainStorm has fully enrolled a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm also recently received U.S. FDA acceptance to initiate a Phase 2 open-label multicenter trial in progressive MS and enrollment began in March 2019.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug status designation from the U.S. Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMA) in ALS. BrainStorm has fully enrolled a Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six U.S. sites supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study is intended to support a filing for U.S. FDA approval of autologous MSC-NTF cells in ALS. BrainStorm also recently received U.S. FDA clearance to initiate a Phase 2 open-label multicenter trial in progressive Multiple Sclerosis. The Phase 2 study of autologous MSC-NTF cells in patients with progressive MS (NCT03799718) started enrollment in March 2019. For more information, visit the company's website at http://www.brainstorm-cell.com

Safe-Harbor Statement

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

Excerpt from:
BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update - GlobeNewswire

IRVINE, Calif., Nov. 1, 2019 /PRNewswire/ --AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that it will be presenting at the following regenerative medicine and investor conferences in November:

Society for the Immunotherapy of Cancer (SITC) Annual MeetingOral PresentationPresenter: Dr. Daniela Bota, MD, PhD, University of California, Irvine; AIVITA GBM Principal InvestigatorTitle: Phase II trial of therapeutic vaccine consisting of autologous dendritic cells loaded with autologous tumor cell antigens from self-renewing cancer cells in patients with newly diagnosed glioblastomaTime: November 6-10, 2019Location: Gaylord National Hotel & Convention Center, National Harbor, MD

The Regenerative Medicine Consortium of the Gulf Coast Consortia for Biomedical SciencesOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEOTitle: Clinical and Commercial Application of Scaled Human Stem Cell DerivatesTime: November 8, 4:00 PM CTLocation: Bioscience Research Collaborative, Houston, TX

NYC Oncology Investor ConferenceOral Presentation Presenter: Dr. Hans S. Keirstead, AIVITA Chairman and CEO Title: AIVITA Corporate PresentationTime: November 12, 4:50 PM - 5:10 PMLocation: Rockefeller Center, New York, NY

Society for NeuroOncology Annual MeetingPoster PresentationTitle: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma.Time: November 20-24, 2019Location: JW Marriott Desert Ridge, Phoenix, AZ

About AIVITA Biomedical

AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its therapeutic pipeline and commercial line of skin care products. All proceeds from the sale of AIVITA's skin care products support the treatment of women with ovarian cancer.

SOURCE AIVITA Biomedical, Inc.

Homepage

See original here:
AIVITA Biomedical to Present at Upcoming Regenerative Medicine, Oncology and Investor Conferences in November - PRNewswire

A regenerative medicine company in Vancouver, British Columbia will begin Phase 1 studies in early 2020 for a treatment for nerve damage and degenerative diseases including Alzheimers disease.

NervGen Pharma wants to advance its proprietary therapeutic technology platform, currently in development for spinal cord injury and multiple sclerosis (MS), to generate new treatments for Alzheimer's disease.

The essence of our technology is that it takes the brakes off the bodys repair systems and allows the nervous system to repair itself, said Bill Radvak, the companys executive chairman and co-founder. You can think of it as the bodys nervous system has a housekeeping function that is constantly at work, fixing bad connections with new ones and tidying up redundant ones.

Digital

In a nutshell, the body produces a scar at sites of physical injury such as a spinal cord injury as well as sites of inflammatory damage from neurodegenerative diseases such as multiple sclerosis and Alzheimer's disease. The purpose of the scar is to encapsulate the site of the injury to prevent further damage but it ultimately inhibits the body's reparative mechanisms.

The co-inventor of NervGen's technology, Dr. Jerry Silver, Professor of Neurosciences at Case Western Reserve University's School of Medicine in Cleveland, Ohio, discovered that a component of these scars, a protein called CSPG, inhibits the body's natural ability to regrow and regenerate. NervGen's technology platform removes this inhibition and, via multiple endogenous repair mechanisms, unlocks the nervous system's ability to repair itself in a manner adapted to the site of injury and type of disease, Radvak said. Numerous repair mechanisms, including regeneration, plasticity and remyelination, have been observed in the various animal models such as stroke, spinal cord injury, multiple sclerosis, cardiac arrhythmia and peripheral nerve injury as reported in over a dozen peer reviewed papers.

In the injured state, the new nerves get stuck because the amount of CSPGs increase, and they bind to a receptor called PTPsigma, which is found on nerves, pinning them in place, Radvak explained.

NervGens core technology targets the protein tyrosine phosphatase sigma (PTP), a neural receptor that impedes nerve regeneration. Inhibition of this receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various medical conditions, Radvak said.

NervGen has identified a series of receptor antagonistsdrugs that block or dampen biological response by binding to and blocking a receptor rather than activating it (think beta blockers)including its lead candidate, dubbed the NVG-291 compound, that they say is ready for clinical development. NervGen has been studying the compound to treat spinal cord injury. Now they want to identify other diseases for its use, including Alzheimers.

Our molecules unstick nerves and prevent new ones from getting stuck, he said. This same receptor, PTPsigma, is also found on myelin, or to be more scientifically correct, on OPCs [Oligodendrocyte progenitor cells] which develop into myelin. So, our treatment allows the myelin, which is damaged in MS, to repair itself.

Radvak said NervGen is hopeful the treatment will work in Alzheimers due to the nature of the disease itself. You also find the same problem in Alzheimers diseaseCSPGs are found in the plaques associated with the disease. We are hoping that our treatments can help the body remove the plaques and then allow new nerve connections to regrow. If our theory is correct, we hope that this could one day prevent and even reverse the disease and its terrible effects.

Alzheimer's disease is a progressive neurodegenerative disorder that destroys memory and cognitive functions. Scientists and others estimate 30 million people are affected by the disease globally including 5.8 million in the United States alone. Experts say, by 2025, the number of seniors with Alzheimer's disease could reach 7.1 million, and the prevalence of Alzheimer's disease could reach 13.8 million by 2050. The estimated cost in 2019 of caring for Americans with Alzheimer's disease and other dementias is $277 billion, a number that does not include unpaid caregiving. Of that amount, $186 billion is the cost to Medicare and Medicaid, and $60 billion is for out-of-pocket costs. Alzheimer's disease is currently ranked as the sixth leading cause of death in the United States, but recent estimates indicate that the disease may rank third, just behind heart disease and cancer, as a cause of death for seniors.

As Alzheimers research and development efforts have failed to produce new effective treatments in the last fifteen years, the medical community and pharmaceutical industry are seeking technologies with new approaches through new targets and pathways.

For example, earlier this year drug companies, Biogen and Eisai, announced they were scrapping two phase 3 trials of the investigational anti-amyloid agent aducanumab for Alzheimer's disease based on an interim futility analysis, Medscape reported this week, but in a surprising about-face, new data from the studies mean the drug is back on the table.

A statement released by the drug's manufacturers said a new analysis from the EMERGE trial shows that the drug actually met the primary endpoint of significant reduction in clinical decline, including cognition and function. In the ENGAGE trial, the cohort of patients who received a high dose of aducanumab support the findings from EMERGE, Medscape reported. They note that after consulting with the US Food and Drug Administration (FDA), regulatory approval for the drug is back on track and will be pursued.

"NervGen's platform technology introduces a truly novel approach to treating Alzheimer's disease," George Perry, PhD, said in a statement. Perry is the current editor-in-chief for the Journal of Alzheimer's Disease and professor of biology and Semmes Distinguished University Chair in neurobiology at the University of Texas at San Antonio.. "Work that began in the early 90s has confirmed the importance of the biological effect of proteoglycans in the central nervous system. In particular, the ability to shift microglia from the inflammatory phase to the phagocytic or housekeeping phase, as evidenced in both a spinal cord injury and multiple sclerosis model, is promising as it is the natural reparative process for removal of amyloid plaques. This demonstration of an immunomodulatory effect on the microglia will be of specific interest in the quest for a solution to Alzheimer's disease as the function of the microglia is one of the hot topics in this still evolving story."

Dr. Ernest Wong, NervGen's president and CEO said in a statement the Phase 1a study will be followed by a Phase 1b on subsets of both chronic and sub-acute spinal cord patients and a Phase 2 study on multiple sclerosis in 2021. Chondroitin sulfate proteoglycans (CSPGs} are intimately associated with senile plaques and our work with PTP knockout mice and other data with chondroitinase all suggest a pivotal role for PTP in AD, he said.

NervGen has taken this discovery into industrial development and is turning the platform into drugs to be developed, Radvak said. The NervGen programs are by far the most advancedwe are unaware of anyone else working with this approach. The company also has a number of patents which gives it exclusivity on this scientific approach. If we are successful and get the products to market, they would be a radically different treatment and first-in-class.

And though drug development takes time and several steps, Radvak said he is hopeful a treatment will be available soon. We are about to a big step by starting the first human trials, he said. The Company plans to submit an Investigational New Drug application with the U.S. Food and Drug Administration for NVG-291 with the intention of initiating a Phase 1 human clinical trial on healthy subjects in early 2020 and expansion of that trial in the second half of 2020 to include a cohort of spinal cord injury patients. In addition, NervGen intends to commence a Phase 2 multiple sclerosis clinical trial in early 2021.

This process takes a number of years for the product to get to market but drug development is like a relay race, he continued. Smaller companies develop drugs in the early steps and often hand over to Pharma for late stage development. At this handover, the company or product is sold to the Pharma which has increased capabilities to commercialize.

More here:
New Alzheimer Treatment Could Take The Brakes Off The Bodys Repair Systems Allowing It To Repair Itself - Forbes

MCLEAN, Va.--(BUSINESS WIRE)--The Thought Leadership & Innovation Foundation (TLI) announces today plans to build on its existing Regenerative Medicine Program through a research collaboration with cellular therapy industry leader RenovaCare. As part of TLIs efforts to conduct vital research in regenerative medicine and chronic disease, this initiative aims to innovate methods for reducing complications from burn and diabetic wounds across large populations.

Our research base, collaborative institutions and long history of innovation align with RenovaCares commitment to breakthrough biomedical technologies, says Bill Oldham, founder and chairman of the Board, TLI. The patented RenovaCare SkinGun technology and its ability to ultra-gently spray stem cells could present a special opportunity for investigations and applications in a wide range of regenerative therapies. Working together, our overall goal is to improve the quality, efficiency and effectiveness of patient care by not only developing new treatment methods, but also by making thoughtful and systematic changes to healthcare and health systems.

TLIs Regenerative Medicine program seeks to adapt new strategies based upon sound scientific evidence, utilizing its infrastructure to support the continuation of scientific and medical work, as well as the development of grant-funded research and other initiatives.

Dr. Robin A. Robinson, who is a TLI Fellow, Vice President of Scientific Affairs, RenovaCare, and named one of the top 100 innovators in medicine by Medicine Maker in 2018, states, This exciting collaboration between RenovaCare and TLIs Regenerative Medicine Program is the first step toward the development of meaningful and quality therapeutic treatments that will benefit patients around the world.

About TLI Foundation:

TLI Foundation is a nonprofit foundation focused on driving innovative thinking and action on global issues relating to health, education and economic empowerment. The organization is committed to fostering transformative change and improving the health and well-being outcomes of communities around the world. Visit https://www.thoughtfoundation.org/

About RenovaCare:

RenovaCare, Inc. is a biotechnology company focused on developing first-of-their-kind autologous (self-donated) stem cell therapies for the regeneration of human organs. Initial products under development target the bodys largest organ, the skin. Investigative clinical use of their flagship technology has shown to be promising new alternatives for patients suffering from burns, and chronic and acute wounds. https://www.renovacareinc.com.

Originally posted here:
Thought Leadership & Innovation Foundation to Expand Its Regenerative Medicine Program Through New Collaboration with RenovaCare - Business Wire

Global Regenerative Medicine Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024 is the most important research for who looks for complete information about the Regenerative Medicine market. The report takes a critical look at the business regulatory framework, technological advances in associated industries, and strategic approaches. For market demand, size, trading, supply, competitors, and prices as well as global predominant vendors information, the report covers all information on the global and regional markets including old and future trends. The research study also explains upcoming industry supply, market demand, value, application, type, share, competition and its analysis of key players with industry forecast from 2019 to 2024.

The research report commits different factors affecting Regenerative Medicine industry such as past data and market trends, technological advancements, upcoming innovations, market risk factors, market restraints, and challenges in the industry. The study then describes the drivers and restraints for the market along with the impact they have on the demand over the forecast period. It also observes the latest trends and development plans, patterns, and policies observed in the global market.

DOWNLOAD FREE SAMPLE REPORT: https://marketandresearch.biz/sample-request/91858

This report includes the following top vendors in terms of company basic information, product category, sales (volume), revenue (Million USD), price and gross margin (%). They are: ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter,

On the basis of types, the market is primarily split into Mono Avalanche Airbags, Dual Avalanche Airbags

On the basis of applications, the market covers: Skiing, Climbing, Hiking, Others

On the basis of geography, the market covers: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

How Far Does The Scope of This Research Study Traverse?

ACCESS FULL REPORT: https://marketandresearch.biz/report/91858/global-regenerative-medicine-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024

Key Market Dynamics: The global Regenerative Medicine market research report forecasts the latest market trends, development methods, and research methodologies. Several factors that are directly affecting the market such as the strategic production and methods, development platforms, and the product model, as well as the minute change within the product profile, are included in the report.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketandresearch.biz), who will ensure that you get a report that suits your needs.

Ron is a very well known face in the journalism world. He is the editor-in-chief of Top News Herald. He covers Business news for Top News Herald. He lives in Buffalo New York with his wife Melinda.

See more here:
Global Regenerative Medicine Market 2019 Worldwide Industry Analysis to 2024 - Top News Herald

BOTHELL, Wash., Oct. 31, 2019 /PRNewswire/ --BioLife Solutions, Inc. (BLFS), a leading developer and supplier of best-in-class bioproduction tools for cell and gene therapies, ("BioLife" or the "Company"), today announced that the Company's third quarter 2019 financial results will be released after market close on Tuesday, November 12, 2019, and that the Company will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) that afternoon. Management will provide an overview of the Company's financial results and a general business update.

Cell and gene therapy tools. (PRNewsfoto/BioLife Solutions, Inc.)

To access the webcast, log on to the Investor Relations page of the BioLife Solutions website at http://www.biolifesolutions.com/earnings. Alternatively, you may access the live conference call by dialing (844) 825-0512 (U.S. & Canada) or (315) 625-6880 (International) with the following Conference ID: 7207519. A webcast replay will be available approximately two hours after the call and will be archived on http://www.biolifesolutions.com for 90 days.

About BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools. Our proprietary CryoStor freeze media and HypoThermosol shipping and storage media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our recently acquired ThawSTAR family of automated cell thawing products and evo cold chain management system reduce therapeutic and economic risk for cell and gene therapy developers by reducing the potential of administering a non-viable dose. For more information, please visit http://www.biolifesolutions.com and follow BioLife on Twitter.

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-to-report-third-quarter-2019-financial-results-and-provide-business-update-on-november-12-2019-300949616.html

The rest is here:
BioLife Solutions to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019 - Yahoo Finance

POMPANO BEACH, FL, Oct. 29, 2019 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC/PK:BSEM) today announced Henry Van Vurst would be stepping down as the company's Chief Executive Officer and as Chairman of the Board of Directors, effective October 22, 2019. Henry is yielding the position to focus on sales and business development for the companys life sciences division. The BioStem Board of Directors has elected Jason Matuszewski, a co-founder and longtime member of the executive team, as the company's interim Chief Executive Officer and Chairman, effective October 22, 2019.

"The Board of Directors of BioStem Technologies has accepted Henrys decision to step down as CEO and Chairman to focus on business development and sales, said Jason Matuszewski. Matuszewski continued, as one of the founders of BioStem Technologies, I have a profound commitment to the success of our company and to ensure the continual focus of our vision and the execution of our strategy. I am fully invested in reassuming the role of CEO until such a time that this important responsibility can be transitioned to the right person following a systematic search that will allow us to maintain our focus on our important fourth quarter.

The company also announced the expansion of its leadership team with the addition of Ken Warrington, PhD as Senior Vice President of Operations. Dr. Warrington brings significant expertise in biopharmaceutical product development and cGMP production. Dr. Warrington will play a key role in the expansion of the laboratory production and development initatives as BioStem continues to accelerate its growth of the BioStem Life Sciences division.

About BioStem Technologies, Inc.(OTC PINK: BSEM):BioStem Technologies, Inc.is a global life sciences corporation, providing innovative technologies with a concentration in Regenerative Medicine. The companys mission is to discover, develop and produce the most effective Regenerative Medicine products in the world. The company is comprised of a diverse group of scientists, physicians, and entrepreneurs who collaborate to create innovative products. These technologies improve the Quality of Life for our patients and, as a result, drive shareholder value.

BioStem Life Sciences, Inc.A company focused on the development of the highest quality birth tissue products for multiple sectors of healthcare. BioStem Life Sciences offers a comprehensive portfolio of high quality brands that include Rheo, Vendaje and Vendaje Optic. BioStem Life Sciences also provides leading class contract manfuactuing services to GMP and GTP standards for companies looking to develop birth tissue products, from bench top to comericalization. For the latest news and information about BioStem Life Sciences and its brands, please visitwww.biostemlifesciences.com

Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

BioStem Technologies, Inc.Phone: 954-380-8342 Website: http://www.biostemtechnologies.com Email: info@biostemtech.comTwitter: @BiostemtechFacebook: BioStem Technologies

Investor Relations:Andrew Van Vurstinfo@biostemtech.com(954) 380-8342

The rest is here:
BIOSTEM TECHNOLOGIES, INC. ANNOUNCES CORPORATE UPDATE; RESIGNATION OF CHAIRMAN AND CEO, APPOINTMENT OF INTERIM CEO AND CHARIMAN; BOARD INITIATES...

Most cancers kill because tumor cells spread beyond the primary site to invade other organs. Now, a USC study of brain-invading breast cancer cells circulating in the blood reveals they have a molecular signature indicating specific organ preferences.

The findings, which appear in Cancer Discovery, help explain how tumor cells in the blood target a particular organ and may enable the development of treatments to prevent the spread of cancers, known as metastasis.

In this study, Min Yu, assistant professor of stem cell and regenerative medicine at the Keck School of Medicine of USC, isolated breast cancer cells from the blood of breast cancer patients with metastatic tumors. Using a technique she developed previously, she expanded or grew the cells in the lab, creating a supply of material to work with.

Analyzing the tumor cells in animal models, Yus lab identified regulator genes and proteins within the cells that apparently directed the cancers spread to the brain. To test this concept, human tumor cells were injected into the bloodstream of animal models. As predicted, the cells migrated to the brain. Additional analysis of cells from one patients tumor predicted that the cells would later spread to the patients brain and they did.

Yu also discovered that a protein on the surface of brain-targeting tumor cells helps them to breach the blood-brain barrier and lodge in brain tissue, while another protein inside the cells shield them from the brains immune response, enabling them to grow there.

We can imagine someday using the information carried by circulating tumor cells to improve the detection, monitoring and treatment of the spreading cancers, Yu said. A future therapeutic goal is to develop drugs that get rid of circulating tumor cells or target those molecular signatures to prevent the spread of cancer.

Yu is a member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, and her laboratory is located in the USC Norris Comprehensive Cancer Center.

In addition to Yu, other authors of the study are Remi Klotz, Amal Thomas, Teng Teng, Sung Min Han, Oihana Iriondo, Lin Li, Alan Wang, Negeen Izadian, Matthew MacKay, Byoung-San Moon, Kevin J. Liu, Sathish Kumar Ganesan, Grace Lee, Diane S. Kang, Michael F. Press, Wange Lu, Janice Lu, Bodour Salhia and Frank Attenello, all of the Keck School of Medicine; Sara Restrepo-Vassalli, James Hicks and Andrew D. Smith of USC Dornsife College of Letters, Arts and Sciences; and Charlotte S. Walmsley, Christopher Pinto, Dejan Juric and Aditya Bardia of Massachusetts General Hospital.

The study was supported by grants from the National Institutes of Health (DP2 CA206653) the Donald E. and Delia B. Baxter Foundation, the Stop Cancer Foundation, the Pew Charitable Trusts and the Alexander & Margaret Stewart Trust, the SC CTSI pilot grant (UL1TR001855 and UL1TR000130), a California Institute for Regenerative Medicine (CIRM) postdoctoral fellowship and a CIRM Bridges award (EDUC2-08381), and the National Cancer Institute (P30CA014089).

More stories about: Cancer, Research

See the original post:
New study reveals why breast cancer spreads to the brain - USC News

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Photo: Dan Haar / Hearst Connecticut Media / Dan Haar / Hearst Connecticut Me

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Cindi Bigelow, CEO of Bigelow Tea in Fairfield

Innovation TED Talks coming to Fairfield University

FAIRFIELD Fairfield University will host a diverse line-up of speakers at a TEDx program on October 28.

TED stands for Technology, Entertainment, and Design topics that combined in 1984 to form the first TED Talk in Monterey, Calif.

Today, the idea has been expanded to sharing ideas worth spreading. TEDx, programs launched in 2009 to share TED-worthy ideas on a smaller scale.

Featured in the Fairfield U event at Wien Experimental Theatre of the Regina A. Quick Center for the Arts will be a current student, an alumna, an honorary degree recipient, and a faculty member, as well as individuals in health care, education, business, and technology.

Doors open at 2 p.m. and the event is free but registration is required. While TEDx audiences are capped at 100 to promote an intimate live experience, overflow attendees will be invited to watch the presentations via live-stream in the adjacent Kelley Theatre.

The theme for the event will be Innovation and Inspiration, in honor of the 25th anniversary of the university's School of Engineering.

The nine speakers include:

* Dr. Stephen F. Badylak, deputy director of the McGowan Institute for Regenerative Medicine.

* David C. Banks, president and CEO of The Eagle Academy Foundation, Inc.

* Cindi Bigelow, the third-generation president and CEO of Bigelow Tea, headquartered in Fairfield.

* Dr. Donna Coletti, scholar-in-residence at the Egan Schools Kanarek Center for Palliative Care.

* Lilliana Delmonico Class of 2020 and a bioengineering major in the School of Engineering and co-founder of the Biomedical Engineering Society at Fairfield University.

* Dr. T. Sloane Guy, professor of surgery and director of Minimally Invasive & Robotic Cardiac Surgery at Thomas Jefferson University Hospital.

* Aidan Kehoe, founder and CEO of Skout Cybersecurity.

* Dawne Ware, Class of 1989 and CEO of Ware Consulting LLC.

* Mark Unger, owner and director of Unger Global Companies, who wrote his book First Survivor, to honor those who helped him reject the diagnosis of zero chance of survival when his son was diagnosed with childhood cancer.

Excerpt from:
Innovation TED Talks coming to Fairfield University - CTPost

Phoenix,AZ(October 11, 2019) AxolotlBiologix, an innovative biotechnology leader in regenerative medicine,announced it has obtained HealthcareCommon Procedure Coding System (HCPCS) billing codes from the Centers forMedicare and Medicaid Services (CMS) for all its products effective October 1,2019.

Were thrilled that the CMS has made it easier forhealthcare providers to get reimbursed for treatments using Axolotl products,said Gary Lauterbach, CEO of AxolotlBiologix. Axolotls products are already part of the GSAs FederalSupply Schedule and areavailable through Indian Health Services and Veterans Affairs. Issuance of these HCPCS Q-Codes by CMS will help simplify thereimbursement process making it easier to utilize our regenerative products.

AxolotlsDualGraft and Axolotl Graft products have been assigned the code Q4210.Axolotls DualGraft is a bi-layered human amnion membrane patch that protectswounds while serving as a barrier to help encourage skin repair andreconstruction. DualGraft is a double-layered amniotic membrane convenientlypackaged as a dehydrated allograft, which can be stored at room temperature andapplied without special instruments in a clinical setting.

AxolotlAmbient and Axolotl Cryo products were assigned the code Q4215. AxolotlAmbient and Axolotl Cryo products are liquid allografts derived from theamniotic components of the placenta to promote regeneration and repair ofdamaged or degenerated tissue. The Ambient product is a liquid allograft that can be stored at an ambienttemperature (257C, 7713F).

For more information on Axolotl products visit http://www.axobio.com

About Axolotl Biologix:

Axolotl Biologix, Inc.is an innovative biotechnology leader in regenerative medicine throughresearch, technology and clinical application. Axolotl Biologix is expandingthe human bodys ability to regenerate by developing and manufacturingregenerative human cell and tissue medical technologies that are disruptingtraditional, more invasive, painful and expensive treatment protocols. For moreinformation, visit http://www.axobio.com

Media Contact:

JoshWeiss

10 to 1Public Relations

josh@10to1pr.com

480-789-0743

Read the original here:
Centers for Medicare and Medicaid Services Makes It Easier for Healthcare Providers to Choose Axolotl Biologix Products to Spur Wound and Tissue...

Antleron has created an R&D facility at their headquarters in Leuven, Belgium - a location known as an incubator for medical and life science innovation, including regenerative medicine, to support and validate customer projects in the field of 3D bioprinting. Antleron's 'living therapy factory' mergescells, biomaterials, biologics, bioreactors and 3D Systems printers to accelerate the engineering of living therapies. Using quality-by-design and artificial intelligence the Antleron multidisciplinary specialists translate these core technologies into pioneering workflows that turn cells into therapies.

The 3D Systems/Antleron relationship addresses solutions for medical device and advanced therapy medicinal product (ATMP) applications, incorporating a variety of innovative technologies that are of benefit to biomedical manufacturing process, beginning with 3D Systems' ProJet MJP 2500and Figure 43D printers and existing portfolio of 21 biocompatible, USP Class VI materials; 3D Sprintand 3DXpertsoftware, and post-processing equipment and processes. The goal is to establish a flexible, scalable Digital Factory approach, built on modular, closed parametric processes which include digital monitoring and quality control for risk mitigation. An example is to advance the way cells and tissues are grown to enable the transition from a static 2D to bioreactor-based 3D cell culture. This can lead to new ways to manufacture functionalized medical implants, vaccines, cell therapies, and living tissues.

According to Antleron CEO, Jan Schrooten, "The vision of Antleron is to sustainably bring living therapies into the clinic. 3D printing is key to this endeavor, and we are eager to collaborate with 3D Systems and its experts. I look forward to the pioneering solutions we'll be able to achieve to elevate the efficacy of bioprinting and extend its biomedical application reach."

"3D Systems is excited about working with Antleron as they explore bioprinting, and especially their capability to develop end-to-end solutions utilizing the 3D Systems' state of the art printing platforms and materials," said Chuck Hull, co-founder and chief technology officer, 3D Systems. "As we look to the future, bioprinting and regenerative medicine are large opportunities for 3D printing, and we look forward to expanding the role 3D Systems will play in these exciting fields."

At Formnext 2019 to be held November 19-22, 3D Systems (booth D03, hall 12.1) and Antleron will exhibit for the first time what is in store for next-generation medical applications with the ProJet MJP 2500 printer and VisiJet materials.

Forward-Looking StatementsCertain statements made in this release by or in reference to 3D Systems that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as "believes," "belief," "expects," "may," "will," "estimates," "intends," "anticipates" or "plans" or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management's beliefs, assumptions and current expectations and may include comments as to the company's beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings "Forward-Looking Statements" and "Risk Factors" in 3D Systems' periodic filings with the U.S. Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or review any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise.

About 3D Systems More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading AM solutions company, it empowers manufacturers to create products and business models never before possible through transformed workflows. This is achieved with the Company's best-of-breed digital manufacturing ecosystem - comprised of plastic and metal 3D printers, print materials, on-demand manufacturing services and a portfolio of end-to-end manufacturing software. Each solution is powered by the expertise of the company's application engineers who collaborate with customers to transform manufacturing environments. 3D Systems' solutions address a variety of advanced applications for prototyping through production in markets such as aerospace, automotive, medical, dental and consumer goods. More information on the company is available at http://www.3dsystems.com.

About AntleronAntleron is a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. The company's nimble team is revolutionizing medicine by merging the potential of cells, biomaterials, biologics, 3D printing and bioreactors to accelerate the engineering of living therapies - empowering patients with fully personalized, regenerative care. Antleron translates core technologies including additive manufacturing (AM), quality-by-design and artificial intelligence into pioneering workflows that turn cells into living therapies to eventually make organ manufacturing a reality. To support its mission, Antleron's business philosophy is to create sustainable ventures that bring living, personalized therapies from idea to patient through risk & reward sharing partnerships. From the company's headquarters in Belgium, Antleron operates at the cutting edge between life sciences and technology within Europe's leading biotech ecosystem. More information on the company is available at http://www.antleron.com.

SOURCE 3D Systems

http://www.3dsystems.com

See the rest here:
3D Systems and Antleron Collaborating to Accelerate 3D Printing Biomedical Breakthroughs - PRNewswire